Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Sep 6:2022:8028846.
doi: 10.1155/2022/8028846. eCollection 2022.

Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis

Min Zhao #  1 , Xinyu Shi #  2 , Jing Zhang  1 , Shengming Deng  1 , Yeye Zhou  1 , Runze Wen  1 , Yixing Lu  1 , Bin Zhang  1
Affiliations
Meta-Analysis

Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis

Min Zhao et al. Comput Math Methods Med. .

Abstract

Background: The incidence of papillary thyroid microcarcinoma (PTMC) has significantly increased in recent years, and the decision to use radioactive iodine (RAI) ablation in low-risk (LR) and intermediate-risk (IR) patients is controversial. The aim of this study was to evaluate whether RAI ablation can reduce the recurrence rate in LR-IR PTMC patients.

Methods: A comprehensive literature search of the PubMed, Embase, Cochrane Library, and Web of Science was conducted according to the PRISMA statement.

Results: There were 8 studies in English that fit our search strategy, and a total of 2847 patients were evaluated. The results of the meta-analysis showed RAI ablation in LR-IR PTMC patients did not reduce cancer recurrence (risk radio (RR) 0.56, 95% CI 0.19-1.70, P = 0.31). Nevertheless, we further performed data analysis and found that IR PTMC patients without RAI ablation had a higher rate of cancer recurrence than those who underwent RAI ablation (RR 0.23, 95% CI 0.11-0.49, P = 0.0001). Furthermore, patients with risk factors for lymph node metastasis (RR 0.16, 95% CI 0.06-0.42, P = 0.0002), microscopic extrathyroidal extension (RR 0.19, 95% CI 0.06-0.60, P = 0.005), and multifocality (RR 0.13, 95% CI 0.04-0.45, P = 0.001) in the absence of RAI ablation were more likely to have recurrence.

Conclusions: Based on our current evidence, RAI ablation can reduce the cancer recurrence rate over 5 years in IR PTMC patients, especially when patients have some risk factors, such as lymph node metastasis, microscopic extrathyroidal extension, and multifocality.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart of study selection.
Figure 2
Figure 2
A forest plots that details any recurrence in LR-IR PTMC patients.
Figure 3
Figure 3
A forest plots that details the locoregional recurrence in LR-IR PTMC patients.
Figure 4
Figure 4
A forest plots that details the recurrence in patients with IR PTMC.
Figure 5
Figure 5
A forest plots that details the recurrence in PTMC patients with some risk factors (lymph node metastasis, microscopic extrathyroidal extension, and multifocality).
Figure 6
Figure 6
Funnel plot. SE: standard error; RR: risk radio.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sobin L. H. Histological typing of thyroid tumours. Histopathology . 1990;16(5):p. 513. doi: 10.1111/j.1365-2559.1990.tb01559.x. - DOI - PubMed
    1. Davies L., Welch H. G. Current thyroid cancer trends in the United States. JAMA Otolaryngology–Head & Neck Surgery . 2014;140(4):p. 317. doi: 10.1001/jamaoto.2014.1. - DOI - PubMed
    1. Arora N., Turbendian H. K., Kato M. A., Moo T. A., Zarnegar R., Fahey T. J. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? Thyroid . 2009;19(5):473–477. doi: 10.1089/thy.2008.0185. - DOI - PubMed
    1. Yu X. M., Wan Y., Sippel R. S., Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Annals of Surgery . 2011;254(4):653–660. doi: 10.1097/SLA.0b013e318230036d. - DOI - PubMed
    1. Siraj A. K., Parvathareddy S. K., Qadri Z., et al. Annual hazard rate of recurrence in middle eastern papillary thyroid cancer over a long-term follow-up. Cancers . 2020;12(12):p. 3624. doi: 10.3390/cancers12123624. - DOI - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts